Elesclomol is being developed under a global collaboration agreement between Synta Pharmaceuticals and GlaxoSmithKline and is not approved for marketing by the FDA or any other similar regulatory body in any country.
Safi Bahcall, president and CEO of Synta, said: “Today’s milestone represents a terrific achievement on the part of the full Symmetry team – the Synta employees, physicians, nurses, healthcare professionals and our partners around the world who came together to enroll one of the largest pivotal trials for a new agent in this disease so rapidly and effectively.
“We intend to conduct the primary endpoint analysis with the same attention to detail and high standards of excellence; our goal is to complete this analysis by May 2009. We are hopeful that this effort on the part of so many will translate into a new therapy for patients.”